Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

62 results about "Gallbladder cancer" patented technology

Tumor that develops in the gallbladder, a small organ below the liver.

Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

InactiveUS20150132253A1Effectively preventingEffectively treatingHeavy metal active ingredientsOrganic active ingredientsDiseaseCombined Modality Therapy
The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Owner:ASTELLAS PHARMA INC +1

ERBB signal pathway mutation targeted sequencing method for prognosis evaluation of gallbladder carcinoma

The invention relates to an ERBB signal pathway mutation targeted sequencing method for the prognosis evaluation of gallbladder carcinoma and provides an application of an ERBB signal pathway mutation targeted sequencing reagent / kit for gallbladder carcinoma patients. In the invention, the whole-genome exon technology is adopted for performing mutation target sequencing of the ERBB signal pathway of a gallbladder carcinoma patient; and in combination with the pathological clinical data of the gallbladder carcinoma patient, the Kaplan-Meier survival curve analysis indicates that the lifetime of the patient after operation is closely related to the gene mutation of the ERBB signal pathway, and the multiple-factor analysis of Cox risk regression model indicates that the gene mutation of the ERBB signal pathway can serve as an independent prognosis factor of gallbladder carcinoma. The prompt of screening the ERBB signal pathway related gene mutation of the gallbladder carcinoma cancer is favorable to the gene-level diagnosis and parting of gallbladder carcinoma, the establishment of therapeutic target, the prognosis analysis and the like.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Pharmaceutical composition for treatment and/or prevention of gallbladder cancer

Provided is an antibody effective for treatment and / or prevention of gallbladder cancer. A pharmaceutical composition for treatment and / or prevention of gallbladder cancer contains as an active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein.
Owner:TORAY IND INC

Methods and biomarkers for detection of gastrointestinal cancers

The present invention relates to methods and biomarkers (e.g., epigenetic biomarkers) for detection of gastrointestinal cancers (e.g., colorectal cancer, gastric cancer, pancreatic cancer, liver cancer, cancer of the gall bladder and / or bile ducts (e.g., cholangiocarcinoma)) in biological samples (e.g., tissue samples, stool samples, blood samples, plasma samples, cell samples, gall samples, bile samples, serum samples).
Owner:UNIV OSLO HF

Anti-cancer agent

The invention relates to an anti-cancer agent containing α-chain protein (α-fragment) of HGF (hepatocyte growth factor) as an active ingredient. The active ingredient of α-fragment has a specific suppressing effect on invasion and metastasis of cancer cells such as gallbladder cancer, lung cancer and other, which are highly metastatic and result in a high mortality. Therefore, the agent of the invention is used in treatment and prevention of cancer as an anti-cancer agent, and is extremely useful clinically.
Owner:NAKAMURA TOSHIKAZU

Model for evaluating HR defect and application

The present invention discloses a model for evaluating an HR defect and its application. Based on a tumor individualized chemotherapy strategy, the method evaluates whether HR in gallbladder cancer cells is defective by using an existing HR-related indicator, and inhibits autophagy and PARP treatment according to normal HR or defective HR, improves the anti-tumor efficacy of a chemotherapy regimenFAM, and avoids the occurrence of resistance after multiple rounds of highly toxic medication for the patient. A multi-molecular marker used for detecting gallbladder cancer cells contains only 15 genes, is liable to clinical trials, reduces the cost of detection, and is not affected by the batch effect of experiments or the difference in the detection platforms, does not require data standardization between multiple samples before use, and is easy to use.
Owner:ZHEJIANG UNIV

Method for preparing human gallbladder cancer cell line resistant to oxaliplatin

The invention provides a method for preparing a human gallbladder cancer cell line resistant to oxaliplatin. The method comprises the following steps that human gallbladder cancer cells in the exponential phase are inoculated in a DMEM culture solution containing newborn fetal calf serum for culturing, oxaliplatin is added into the culture solution for inducing, wherein after the cells recover thenormal growth, the concentration increases progressively, when the cells can normally grow and perform passage at the concentration of 0.5 [mu] mol / L, oxaliplatin is adopted for carrying out impact culture, a culture medium with the concentration of oxaliplatin being 0.5 [mu] mol / L is used for culturing, after the cells grow and perform passage stably, impact is carried out again, then the concentration increases progressively, oxaliplatin is used for carrying out impact inducing till the cells can grow in oxaliplatin of 10.0 [mu] mol / L, and finally, the human gallbladder cancer cell line resistant to oxaliplatin which can stably grow and perform passage in the culture system containing 10.0 [mu] mol / L of oxaliplatin is obtained. The method for establishing the human gallbladder cancer cell line resistant to oxaliplatin is simple, convenient and feasible, the establishing time is short, and the drug resistance index is close to 20.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV +1

Method for establishing prediction model for survival benefit of gallbladder cancer patient after chemoradiotherapy

The invention relates to a method for establishing a prediction model for survival benefit of a gallbladder cancer patient after chemoradiotherapy. The method comprises the steps of acquiring clinical and pathological data of the gallbladder cancer patient; dividing the acquired data into a plurality of groups of data according to the TNM stages, and respectively judging whether the patient in each stage is benefited from adjuvant therapy or not; dividing the data corresponding to the TNM stages into a modeling group and an internal verification group; analyzing the prediction capability of clinical and pathological variables of the modeling group data on the total survival time OS through a single-factor COX risk scale model, and screening risk factors which significantly influence the total survival time OS of the patient in the modeling group; incorporating the screened risk factors into a multi-factor COX risk scale model for analysis, and screening out influence variables significantly influencing the total survival time OS of the patient; according to the obtained influence variables, drawing a column graph used for predicting the total survival time OS, and obtaining a prediction model; and verifying the model. Compared with the prior art, the method has the advantages of providing credible prediction and analysis results for the GBC patient, being simple and convenient to operate and the like.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV

Pharmaceutical composition for treatment and/or prevention of gallbladder cancer

Provided is an antibody effective for treatment and / or prevention of gallbladder cancer. A pharmaceutical composition for treatment and / or prevention of gallbladder cancer contains as an active ingredient an antibody or a fragment thereof having immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising at least seven consecutive amino acid residues of the amino acid sequence of the protein.
Owner:TORAY IND INC

Method for inhibiting tumor growth by DDX24 helicase point mutation and application of DDX24 helicase

The invention discloses a newly discovered cancer promoting effect of DDX24 helicase, a method for realizing a cancer inhibition effect through point mutation and application of the DDX24 helicase. The contents of the invention comprise: 1, high expression of wild type DDX24 has significant correlation with tumor growth, and the growth of tumors can be promoted through high expression of the wildtype DDX24; 2, different from the mechanism of the pathogenic gene DDX24 for familial vascular malformation, DDX24 point mutation including K11E or E271K obviously inhibits the growth of tumors; 3, based on the new function and induced point mutation of DDX24 provided in the invention, a novel targeted therapy method can be provided for treatment of latent and refractory tumors, and a new thoughtcan also be provided for preparation of tumor-related vaccines; and 4, application of 1-3 described above is provided. The point mutation can be used for treating solid tumors including, but not limited to, squamous cell carcinoma of the head and the neck, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, skin melanoma, lymphoma, adenoma, thoracic adenoma, lung cancer, colorectal cancer, gallbladder cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, nasopharyngeal cancer, bone cancer andmalignant myoma.
Owner:THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV

Application of ulinastatin in preparation of drug for treating gallbladder carcinomas

The invention belongs to the technical field of medicines, and particularly discloses application of ulinastatin in preparation of a drug for treating gallbladder carcinomas. It is proved through animal experiments that ulinastatin has an obvious inhibiting effect on human gallbladder carcinoma transplanted tumor in nude mice, is low in toxic and side effects and high in safety and can serve as a drug for treating the gallbladder carcinomas for use.
Owner:GUANGDONG TECHPOOL BIO-PHARMA CO LTD

Liver and gallbladder cancer cell postoperative monitor based on overall association medical logic and use method of liver and gallbladder cancer cell postoperative monitor

The invention discloses a liver and bile cancer cell postoperative monitor based on overall association medical logic, which comprises a special earphone worn on the two ears of a patient, and the special earphone comprises a transmitter and a receiver; the special earphone is electrically connected with a noise voltage generator, and the noise voltage generator is connected with a processor through a differential amplifier; the processor is connected with the pulse width modulation circuit; the invention further discloses a use method of the liver and bile cancer cell postoperative monitor based on the overall association medical logic, and the use method comprises the steps that S1, a detected person wears the specially-made earmuff, electromagnetic waves are emitted through the left earmuff and reach the cerebral cortex, and an external magnetic field is generated through electromagnetic resonance; the method is simple, the neurons can be stimulated to generate chemical electric signals, the chemical electric signals are transmitted to tissue cells of organs of the whole body through the neurons to cause resonance, and the disease state and degree of the human cell level are judged after analysis so as to count significance and predict clinical feature significance.
Owner:芭雅医院投资管理(上海)有限公司

Big data-based liver and bile cancer cell postoperative monitor and use method thereof

The invention discloses a liver and bile cancer cell postoperative monitor based on big data, which comprises a detection device being a special earphone, wherein the detection device is electrically connected with a data transmission device, the data transmission device is electrically connected with a processor, and the processor is connected with a medical system and a cloud server; thus, the early warning is carried out on diseases through the medical system and the cloud server. The invention further discloses a using method of the liver and bile cancer cell postoperative monitor based on the big data, which comprises the following steps: S1, searching information of a to-be-detected person through the to-be-detected person, and then preparing related information of the to-be-detected person for research. The postoperative monitor is reasonable in structure, neurons can be stimulated to generate chemical electric signals, and the disease state and degree of the human cell level are judged after analysis, so that postoperative treatment of liver and gallbladder cancer cells is facilitated.
Owner:芭雅医院投资管理(上海)有限公司

Honey health preserving wine

The invention discloses a honey health preserving wine, which comprises the following raw materials and auxiliary materials: 3 g of honeybee pupae, 3 g of bee, 3 g of honey, 10 g of red date, 10 g ofChinese wolfberry, 5 g of millettia speciosa champ, 500 g of Baijiu with an alcoholicity of 62 DEG, and 10 g of longan. According to the present invention, leaching, extraction of the medicinal components of honey and bee venom and prepared fermentation with high-concentration Baijiu are performed, and finally the high-alcohol-concentration honey health preserving wine is obtained through the secondary fermentation; the honey health preserving wine has advantages of stable performance, good efficacy, golden color, unique fragrance and delicious taste, has effects of wind dampness removing, wind cold removing, blood pressure lowering, paralysis treating, impotence treating, prospermia treating, blood fat lowering, face nourishing, blood enriching and qi supplementing, contains the medicinalcomponents of bee venom, can be used for treating chronic bronchitis, can further be used for the assisted treatment of acquired immunodeficiency syndrome, lung cancer, gallbladder cancer and other cancers, can be used for coated treatment of psoriasis and eczema, and has significant treatment effects.
Owner:海南鑫元利酒业有限公司

Traditional Chinese medicine composition for use after gallbladder cancer surgery and preparation method thereof

The invention relates to a traditional Chinese medicine composition for hepatological surgery department, in particular to a traditional Chinese medicine composition for use after gallbladder cancer surgery and a preparation method thereof. A pharmaceutical for oral administration is prepared from the following components in parts by mass: 3-5 parts of white rhizoma Et radix polygoni-cuspidatl, 5-10 parts of poria cocos, 5-8 parts of longan, 3-5 parts of rhodiola rosea, 3-5 parts of peperomia blanda, 5-8 parts of soybean, 3-5 parts of garden burnet, 3-5 parts of radix ophiopogonis, 3-5 parts of rhizoma panacis majoris, 5-8 parts of liquorice root, 5-8 parts of water chestnut hull, 3-5 parts of gynostemma pentaphyllum, 3-5 parts of loquat, 5-8 parts of Chinese Date, 5-8 parts of Chinese angelica, 5-8 parts of pilose antler and 5-8 parts of lucid ganoderma; a pharmaceutical for external use is prepared from the following components in parts by mass: 3-5 parts of chinaroot greenbrier, 5-8 parts of tangerine pith, 3-5 parts of catbrier, 5-8 parts of resina liquidambaris, 5-8 parts of plant soot, 5-8 parts of bletilla striata, 3-5 parts of radix cynanchi bungei, 3-5 parts of thyme and 3-5 parts of lignum dalbergiae odoriferae. According to the traditional Chinese medicine composition disclosed by the invention, the pharmaceutical for oral administration is cooperated with the pharmaceutical for external use to take effect; the pharmaceutical for oral administration has the advantages of tonifying qi, promoting blood circulation and detoxication, and can facilitate effect of the pharmaceutical for external use for stopping bleeding and promoting healing; and meanwhile the pharmaceutical for external use can stop bleeding and dredging collaterals, and can facilitate effect initiation of the pharmaceutical for oral administration.
Owner:江志杰

Application of ulinastatin-containing pharmaceutical composition to preparation of medicine for treating carcinoma of gall-bladder

The invention belongs to the field of medical technology and particularly discloses application of an ulinastatin-containing pharmaceutical composition to preparation of a medicine for treating carcinoma of the gall-bladder. The pharmaceutical composition comprises ulinastatin and beta-aescin natrum. Animal tests verify that the pharmaceutical composition can play an obvious inhibition function on human gall-bladder carcinoma nude-mouse transplanted tumor, is low in toxic and side effect and high in security and can serve as the medicine for treating carcinoma of the gall-bladder.
Owner:GUANGDONG TECHPOOL BIO-PHARMA CO LTD

Kit for early diagnosis of gallbladder cancer and application thereof

The invention relates to a kit for early diagnosis of gallbladder cancer and application thereof. The kit comprises a CTNNB1 mutation detection reagent and an ARID2 mutation detection reagent. According to the invention, senescence is determined to be a main factor for promoting accumulated mutations and CTNNB1 and ARID2 mutations in the tumors, especially CTNNB1 mutation plays a key role. According to the invention, a foundation is laid for early diagnosis and effective treatment of gallbladder cancer through the understanding of reconstruction of gallbladder cancer transformation and canceration evolution trajectory.
Owner:普瑞基准科技(北京)有限公司 +1

Method for specific sorting and identification detection of CTC in serum of biliary tract tumors

The present invention provides a method for specific sorting of CTC in serum of biliary tract tumors. An appropriate amount of peripheral blood from patients with biliary tract tumors is taken and placed in anticoagulation centrifuge tubes and whole blood samples are mixed evenly; the collected blood samples are sequentially subjected to sample processing of plasma protein and plasma nucleic acidremoval, red blood cell removal, layered centrifugation and white blood cell removal; an HSPG antibody or a SDC1 subtype antibody or a SDC2 subtype antibody or a GPC1 subtype antibody or a GPC3 subtype antibody is used to combine with immunomagnetic beads to capture HSPG positive or SDC1 positive or SDC2 positive or GPC1 positive or GPC3 positive CTC. HSPG is used as a relatively specific functional tumor molecular marker for CTC sorting of gallbladder cancer and cholangiocarcinoma, thereby improving sorting efficiency of biliary tract tumor CTC, a set of HSPG-based CTC molecular typing scoring system is established, the high-specificity and high-sensitivity detection method for the biliary tract tumors is otbained, and based on the high-efficiency sorting of the biliary tract tumor CTC, downstream RNA-seq and gene NGS detection is conducted to obtain tumor-specific molecular information to improve specificity.
Owner:易滨 +1

Traditional Chinese medicine combination for treating hepatobiliary diseases and preparation method thereof

The invention discloses a traditional Chinese medicine combination for treating hepatobiliary diseases and a preparation method thereof. The traditional Chinese medicine combination is composed of the following raw materials, by weight, of 200-300 parts of ganoderma lucidum soak solutions, 30-60 parts of antrodia camphorata polysaccharide, 70-100 parts of selenium-enriched pleurotus ostreatus fruiting body powder, 10-20 parts of bear bile powder, 100-200 parts of panax notoginseng powder, 80-120 parts of rock candies and 180-220 parts of tilia honey. The traditional Chinese medicine combination has good curative effect on treating liver cirrhosis, viral hepatitis type B, cholangitis, gallstones, a bile duct cancer and a gallbladder cancer.
Owner:林树芳

Compound containing imatinib and plant polysaccharide

The invention provides a compound containing imatinib or pharmaceutically acceptable salt of the imatinib and plant polysaccharide. The plant polysaccharide is selected from one of ganoderma lucidum polysaccharide, coriolus versicolor polysaccharide and cynanchum otophyllum polysaccharide. Animal tests show that the compound can generate a synergistic anti-tumor effect on liver cancer, gastric cancer, a lung carcinoma model, gallbladder carcinoma and / or kidney cancer.
Owner:黄泳华

Method of treating carcinoma

ActiveUS20180140549A1Organic active ingredientsSolution deliveryVeinHepatic bile
A method of treating patients suffering from carcinoma of intrahepatic or extra hepatic bile duct or gall bladder which is locally advanced or metastatic, by intravenously administering to the patient, paclitaxel in the form of a nanodispersion. The nanodispersion comprises particles with a mean particle size less than 300 nm and is free of polyoxyethylated castor oil and free of a protein.
Owner:SUN PHARMA INDS

A long usnea derivative and its use in the preparation of drugs for the treatment of gallbladder cancer

The invention provides an usnea longifolia derivative and application thereof in preparation of a medicine for treating gallbladder cancer. The usnea longifolia derivative has a chemical name of 3, 6-diacetyl-2, 7, 9-trihydroxy-8, 9b-dimethyl-1 (9bH)-dibenzofuranone, has an effect of inhibiting activity of human gallbladder cancer cells and has a small toxic effect on normal cells. The compound can be independently used in the treatment of gallbladder cancer and can also be used in combination with other drugs. The inventor of the invention unexpectedly finds that the compound can achieve a better effect of inhibiting cholecystoma cancer cells when being combined with cisplatin and can effectively slow down the side effects generated by cisplatin. The medicine for treating the gallbladdercancer has great application potential.
Owner:山西白求恩医院

Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Owner:IMMATICS BIOTECHNOLOGIES GMBH

Application of zedoary cyclic diolefine in preparation of medicine for resisting neoplasm metastasis

The invention belongs to the field of pharmacy, and provides application of zedoary cyclic diolefine in preparation of a medicine for resisting neoplasm metastasis, and in particular relates to application in the preparation of medicines for resisting neoplasm metastasis, such as liver cancer, gastric cancer, carcinoma of urinary bladder, breast cancer, colon cancer, kidney cancer, esophagus cancer, gallbladder cancer, ovarian cancer, pancreatic cancer, carcinoma of uterine cervix, thyroid cancer, prostatic cancer, oral cancer, lung cancer and the like. The zedoary cyclic diolefine plays a role in resisting the neoplasm metastasis through inhibiting the expression of proteins related to neoplasm cell metastasis.
Owner:HANGZHOU MINSHENG PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products